Truist Securities Maintains Buy on Protagonist Therapeutics, Raises Price Target to $121

Benzinga Newsdesk www.benzinga.com Positive 86.5%

Neg 0% Neu 0% Pos 86.5%

Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $110 to $121.